Market Overview

The Global Bleeding Disorders Treatment Market - $23.04 Billion Outlook to 2026 -


The "Bleeding
Disorders Treatment - Global Market Outlook (2017-2026)"
has been added to's offering.

According to the report,The Global Bleeding Disorders Treatment Market
accounted for $11.14 billion in 2017 and expected to grow at a CAGR of
8.4% to reach $23.04 billion by 2026.

Factors like growth in R&D investment for hemophilia products,
inclination towards prophylactic treatment, increasing number of
hemophilia patients, and the emergence of biosimilars products are
fuelling the market growth.

Patent expiry of existing brands provide generic drug manufacturers an
opportunity to enter, as well as sustaining healthcare infrastructure in
developing economies with advancement in technology for development of
new drugs and therapies will provide ample opportunity for the market

The market will also witness emerging trends like high entry barriers
created by local government and low switching rate for hemophilia

However, high cost of hemophilia drugs and inadequate reimbursement and
lack of availability of skilled professionals are hampering the market

North America is attributed to dominate the market during the forecast
period owing to high acceptance for prophylaxis treatment among all age
groups in the U.S. However, Asia Pacific is projected to grow at highest
CAGR during the forecast period, due to increasing awareness of these
disorders and availability of cheap generic drugs in the emerging
economies such as India and China.

Key Topics Covered

1 Executive Summary

2 Preface

3 Market Trend Analysis

4 Porter's Five Forces Analysis

5 Global Bleeding Disorders Treatment Market, By Drug

6 Global Bleeding Disorders Treatment Market, By Type

7 Global Bleeding Disorders Treatment Market, By Therapy

8 Global Bleeding Disorders Treatment Market, By Geography

9 Key Developments

10 Company Profiling

  • Alnylam Pharmaceuticals
  • Amgen Inc.
  • Baxalta (Now Shire)
  • Bayer Pharmaceuticals
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Cangene Corporation
  • CSL Behring
  • Grifols S.A.
  • Janssen Pharmaceuticals
  • Novo Nordisk A/S
  • Octapharma
  • Pfizer Inc.
  • Sanofi
  • Xenetic Biosciences Inc.

For more information about this report visit

View Comments and Join the Discussion!